fbpx Metastatic Colorectal Cancer - Plus Therapeutics (PSTV)
Metastatic Colorectal Cancer

A secondary form of liver cancer with a high level of severity.

Metastatic colorectal cancer (mCRC) is an advanced, stage IV cancer that has spread to the liver from the breast, lung, colon or rectum. About 50%–60% of patients diagnosed with colorectal cancer will develop metastases during the course of their disease. Symptoms may include an overall feeling of weakness and poor health, appetite/weight loss, fever, or fatigue.

Incidence

150K

cases of colorectal cancer diagnosed each year in the U.S., >50% of which will develop into liver metastasis1

Survival

14%

of patients survive 5 years after diagnosis2

Current Treatment Approaches

For a select few, resection of the liver and primary tumor offers the opportunity for improved long-term survival and even a cure. Nevertheless, 80% of patients are not candidates for surgical resection at diagnosis, making their treatment options much more complex.

Patients with unresectable tumors have few safe options.

Typical standards of care beyond surgery include image-guided interventional therapies (ablation, radioembolization, external beam radiation therapy, chemotherapy, and targeted therapy). Radioembolization together with radiosensitizing systemic chemotherapy appears to be an increasingly promising approach, as many studies have shown efficacy in downsizing liver metastases so that resection is possible. However, the lack of precision with current radioembolization therapies causes damage to normal healthy tissue.

The Opportunity

To extend the life of patients with difficult-to-treat mCRC tumors through a safer, more targeted and convenient treatment option.

188RNL-BAM is a next-generation radioembolization therapy designed for the injection of a single high dose of radiation directly into the hepatic artery, blocking the tumor’s blood flow and enhancing delivery. By targeting the tumor more effectively and precisely, we expect 188RNL-BAM will minimize radiation exposure to normal tissues, improving patients’ survival expectancy and quality of life.
Compared to current radioembolization therapies, 188RNL-BAM has strong potential advantages in work-up procedure, radioactivity retention, production cost, drug clearance and general convenience for the patient.

1 Source: Cancer.net; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942404/
2 Source: Cancer.net